Loading…
Cellectar Biosciences, Inc. is projected to rise to $3.43 by 2027, a +22% move from its current price of $2.82. CLRB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.73 | $2.82 | $2.92 | +0.03% |
| Jul 14 | $2.69 | $2.82 | $2.96 | +0.05% |
| Jul 15 | $2.66 | $2.82 | $2.99 | +0.08% |
| Jul 16 | $2.64 | $2.82 | $3.02 | +0.10% |
| Jul 17 | $2.62 | $2.82 | $3.05 | +0.13% |
| Jul 18 | $2.60 | $2.82 | $3.07 | +0.16% |
| Jul 19 | $2.58 | $2.83 | $3.09 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.58 | $2.83 | $3.09 | +0.18% |
| Week 2 | $2.49 | $2.83 | $3.22 | +0.36% |
| Week 3 | $2.42 | $2.84 | $3.32 | +0.55% |
| Week 4 | $2.37 | $2.84 | $3.40 | +0.73% |
| Week 5 | $2.32 | $2.85 | $3.48 | +0.91% |
| Week 6 | $2.28 | $2.85 | $3.56 | +1.10% |
| Week 7 | $2.25 | $2.86 | $3.63 | +1.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cellectar Biosciences, Inc. is a clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate CLR 131 (iopofosine I-131) is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory Waldenström's macroglobulinemia, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for relapsed or refractory pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for relapsed or refractory head and neck cancer.
It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborations with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc.
was founded in 2002 and is headquartered in Florham Park, New Jersey.
CLRB trades as the stock for Cellectar Biosciences, Inc. The current price is $2.83 with a market capitalization of $22.62M and a current rank of 4882. The stock's price outlook is captured in a year-by-year forecast with varying min/avg/max levels and ROI.
The near term shows a neutral posture in 2026, followed by a series of bullish projections in subsequent years.
A major floor 35.5% below — a decisive break under it would weaken the trend.
The nearest floor, 20.9% below — buyers have tended to step in here.
The nearest ceiling, 11.3% above — a clean break opens room to run.
A major ceiling 29.1% above — clearing it would confirm fresh momentum.
Key CLRB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLRB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.75 | Buy | $2.76 | Buy |
| MA 10 | $2.73 | Buy | $2.72 | Buy |
| MA 20 | $2.59 | Buy | $2.69 | Buy |
| MA 50 | $2.80 | Buy | $2.75 | Buy |
| MA 100 | $2.88 | Sell | $2.96 | Sell |
| MA 200 | $3.30 | Sell | $4.77 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.09 | Neutral |
| Stoch RSI (14) | 94.84 | Sell |
| CCI (20) | 92.84 | Neutral |
| Williams %R (14) | -2.78 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 12.80 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 97.22 | Sell |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | 0.06 | Buy |
| Ultimate (7,14,28) | 53.18 | Neutral |
| Momentum (10) | 0.35 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 2.75 | Buy |
| ADX (14) | 12.67 | Neutral |
| ATR (14) | 0.08 | Info |
The near-term technical picture is bullish in sentiment with RSI(14) at 60. The 50-day simple moving average (SMA50) is $2.80 and the 200-day simple moving average (SMA200) is $3.37. Support is at $2.23 and resistance at $3.20. Over the last 30 days, the price has moved between $2.18 and $3.68. Annualized volatility is high at 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.23 | $2.82 | $3.85 | 0% | Neutral | |
| $2.66 | $3.43 | $4.70 | +22% | Bullish | |
| $2.88 | $3.84 | $5.51 | +36% | Bullish | |
| $3.04 | $4.18 | $6.21 | +48% | Bullish | |
| $2.72 | $3.84 | $5.87 | +36% | Bullish | |
| $2.76 | $3.99 | $6.26 | +42% | Bullish | |
| $2.81 | $4.15 | $6.66 | +47% | Bullish | |
| $2.66 | $4.03 | $6.60 | +43% | Bullish | |
| $3.48 | $5.37 | $8.95 | +90% | Bullish | |
| $3.80 | $5.98 | $10.15 | +112% | Bullish | |
| $4.14 | $7.14 | $13.02 | +153% | Bullish | |
| $6.12 | $12.42 | $25.14 | +341% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.23 | $2.82 | $3.42 | +0.00% |
| August 2026 | $2.48 | $2.94 | $3.61 | +4.41% |
| September 2026 | $2.41 | $2.89 | $3.59 | -1.93% |
| October 2026 | $2.31 | $2.79 | $3.51 | -3.24% |
| November 2026 | $2.38 | $2.90 | $3.68 | +3.78% |
| December 2026 | $2.46 | $3.01 | $3.85 | +3.82% |
Click any year to see its month-by-month CLRB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cellectar Biosciences, Inc.'s 2026 outlook centres on $2.82, within a $2.23 to $3.85 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CLRB could reach as high as $4.70, with a base case around $3.43 and support toward $2.66 — roughly +22% from $2.82. Buyers look set to stay in control over this stretch.
Expect CLRB to range from $2.88 to $5.51 through 2028. The $3.84 average target implies a +36% move from current prices. That is up +12% on the projected 2027 average. Momentum favours further upside here.
The CLRB price prediction for 2029 points to an average of $4.18 (low $3.04, high $6.21) — a potential gain of +48% on today's $2.82. Buyers look set to stay in control over this stretch.
In 2030, CLRB is projected to trade between $2.72 and $5.87, averaging $3.84 — a potential gain of +36% from today's $2.82. That is -8% versus the projected 2029 average. Momentum favours further upside here.
Cellectar Biosciences, Inc.'s 2031 outlook centres on $3.99, within a $2.76 to $6.26 range. That is up +4% on the projected 2030 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CLRB could reach as high as $6.66, with a base case around $4.15 and support toward $2.81 — roughly +47% from $2.82. Momentum favours further upside here.
Expect CLRB to range from $2.66 to $6.60 through 2033. The $4.03 average target implies a +43% move from current prices. That is -3% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The CLRB price prediction for 2034 points to an average of $5.37 (low $3.48, high $8.95) — a potential gain of +90% on today's $2.82. Momentum favours further upside here.
In 2035, CLRB is projected to trade between $3.80 and $10.15, averaging $5.98 — a potential gain of +112% from today's $2.82. That is up +11% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Cellectar Biosciences, Inc.'s 2040 outlook centres on $7.14, within a $4.14 to $13.02 range. That is up +19% on the projected 2035 average. That marks a +153% change versus current levels. Momentum favours further upside here.
By 2050, CLRB could reach as high as $25.14, with a base case around $12.42 and support toward $6.12 — roughly +341% from $2.82. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLRB today (≈ 354.609929 CLRB) could be worth
$4,405.72
+$3,405.72 (+341%) by 2050 · US Dollar
Based on the average projected CLRB price of $12.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLRBwould be worth at today's price.
$1,000 invested in CLRB on Jul 10, 2025 (≈ 202.839764 CLRB) would be worth
$572.01
-$427.99 (-42.8%) today · 0.57× · US Dollar
Based on a CLRB entry price of $4.93 vs. today's $2.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.81 | $1,003.56 | +0.4% |
| 1 month ago | $2.26 | $1,247.79 | +24.8% |
| 3 months ago | $2.76 | $1,021.74 | +2.2% |
| 6 months ago | $3.8 | $742.11 | -25.8% |
| 1 year ago | $4.93 | $572.01 | -42.8% |
| All time (5.0y) ago | $333 | $8.47 | -99.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLRB forecast.
Our base-case forecast reaches $5.60 around 2035.
Implied market cap at $5.60: $44.75M
The multi-year forecast shows a rising trajectory in average price and upside potential. In 2026 the avg is $2.83 with a min of $2.23 and a max of $3.92 (sentiment Neutral). In 2027 the avg rises to $3.43 with a max of $4.83 and ROI of 21.2% (Bullish).
In 2028 the avg is $3.92 (ROI 38.5%). In 2029 the avg is $4.22 (ROI 49%). For 2030 the avg is $3.81 (ROI 34.7%), and by 2031-2032 the avg reaches $3.97 and $4.00 with ROIs of 40.4% and 41.3% respectively.
In 2033 the avg is $3.80 (ROI 34.1%). The forecast surges in 2034 to an avg of $5.36 (ROI 89.3%) and in 2035 to $5.93 (ROI 109.4%). The path continues higher with 2040 having an avg of $6.93 (ROI 144.8%) and 2050 an avg of $11.81 (ROI 317.3%).
Overall, the sentiment shifts to bullish in the longer horizon, with substantial upside but these are estimates, not guarantees.
Tap a question to reveal the answer.
2030 forecast: min $2.60, avg $3.81, max $6.06 with ROI 34.7% and bullish sentiment.
The forecast shows bullish sentiment in 2027 onward with rising averages and positive ROIs: 2027 avg $3.43 (ROI 21.2%), 2028 avg $3.92 (ROI 38.5%), 2029 avg $4.22 (ROI 49%), 2040 avg $6.93 (ROI 144.8%), and 2050 avg $11.81 (ROI 317.3%). 2026 is Neutral. These figures are estimates, not guarantees.
Yes, the max forecasts reach above $10 in several years: 2034 max $9.37, 2035 max $10.57, 2040 max $13.38, and 2050 max $25.53.
Current price is $2.83 and market capitalization is $22.62M.
The 30-day range is $2.18 to $3.68, RSI(14) is 60, SMA50 is $2.80, SMA200 is $3.37, and support/resistance are $2.23 and $3.20 respectively. Annualized volatility is 80%.
Cellectar Biosciences, Inc. Community Discussion
0Share your Cellectar Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.